FindTrial
Sign In

Lenvatinib Oral Product

DRUG5 trials

Sponsors

RenJi Hospital, Shanghai First Maternity and Infant Hospital, H. Lee Moffitt Cancer Center and Research Institute, Tongji Hospital, Peking Union Medical College Hospital

Conditions

Biliary Tract NeoplasmsEffects of ImmunotherapyEndometrial CancerHepatocellular CarcinomaHepatocellular Carcinoma RecurrentImmunotherapyLiver Transplant; ComplicationsMerkel Cell Carcinoma

Phase 2

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
Active, not recruitingNCT04869137
H. Lee Moffitt Cancer Center and Research InstituteMerkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
Start: 2021-05-28End: 2026-09-30Updated: 2025-10-31
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT05935579
Peking Union Medical College HospitalBiliary Tract Neoplasms, Immunotherapy
Start: 2022-12-14End: 2024-12-30Target: 40Updated: 2023-11-15

Unknown Phase

Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
NCT04425226
RenJi HospitalHepatocellular Carcinoma Recurrent, Liver Transplant; Complications
Start: 2020-08-06End: 2024-12-30Target: 192Updated: 2020-08-13
Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma
NCT04444193
Shanghai First Maternity and Infant HospitalEndometrial Cancer
Start: 2020-08-31End: 2021-05-31Target: 20Updated: 2020-06-23
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
NCT05420922
Tongji HospitalEffects of Immunotherapy, Hepatocellular Carcinoma, Programmed Cell Death 1
Start: 2021-11-01End: 2022-12-31Target: 2000Updated: 2022-06-15

Related Papers

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.
2026-01-14
A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
Journal of Clinical Oncology2025-05-28
Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: A retrospective cohort study
Liver Research2025-03-082 citations